by The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 9193.23 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Urinary tract infection (UTI) refers to bacterial infection occurring in any part of the urinary system including urethra, bladder, and kidneys. Common symptoms of UTI include frequent urge to urinate, pain or burning sensation while urinating, foul-smelling urine, and abdominal pain. Antibiotics such as fluoroquinolones, aminoglycosides, beta-lactams, and macrolides are commonly used drugs for treatment of UTI. Advancements in diagnostic methods such as urine culture tests and molecular diagnosis enable early detection and treatment of UTIs.
Market key trends:
Growing prevalence of recurrent UTIs due to drug resistance is a major factor driving the market growth. According to American Urological Association, over 60% of women face recurrence of UTI within one year after initial infection. Rising prevalence of diabetes and obesity which compromise urinary tract immunity is also contributing to high incidence of recurrent UTIs. Additionally, launch of novel antibiotics with enhanced efficacy is expected to offer lucrative growth opportunities over the forecast period. For instance, in 2021, Cipla introduced Cipmox XL extended-release tablets for treatment of uncomplicated UTIs in adults.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to the presence of large companies with strong brands and need for extensive R&D for drug development.
Bargaining power of buyers: The bargaining power of buyers is moderate as the demand for drugs for urinary tract infection is consistent.
Bargaining power of suppliers: The bargaining power of suppliers is low as there are numerous raw material suppliers.
Threat of new substitutes: The threat of new substitutes is low as there are limited treatment alternatives available for urinary tract infection currently.
Competitive rivalry: The competitive rivalry is high among existing players due to their robust product portfolio and strong geographic presence.
Key Takeaways
The Global Urinary Tract Infection Therapeutic Market Size is expected to witness high growth, exhibiting CAGR of 3.0% over the forecast period, due to increasing prevalence of urinary tract infections.
North America dominates the global urinary tract infection therapeutic market and is expected to continue its dominance over the forecast period. This is attributed to increasing prevalence of urinary tract infections in the region. Europe is another major market for urinary tract infection therapeutics owing to rising healthcare expenditure.
Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others. Pfizer leads the global market with its broad product offerings for urinary tract infection treatment.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
